Prevention of Seizure-Induced Sudden Death by Stimulating Serotonergic Signaling
通过刺激血清素信号传导预防癫痫引起的猝死
基本信息
- 批准号:10311540
- 负责人:
- 金额:$ 38.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-01 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:5-HydroxytryptophanAgonistAmygdaloid structureAnimal ModelAnimalsAttenuatedBrainCause of DeathCessation of lifeCitalopramClinicalCouplingDBA/1 MouseDataDevelopmentDisease modelDorsalElectrocardiogramElectroencephalographyElectrophysiology (science)EpilepsyEventExhibitsFenfluramineFluoxetineFosteringFunctional disorderGeneral PopulationGoalsHTR2A geneHumanInterventionKnowledgeLiteratureMidbrain structureMissionModelingMonitorMusNational Institute of Neurological Disorders and StrokeNeuronsOutcomeParoxetinePatientsPharmaceutical PreparationsPharmacologyPlethysmographyPre-Clinical ModelPreventionPrevention strategyPreventivePublic HealthReducing AgentsReportingResearchRiskRoleSeizuresSerotoninSerotonin AntagonistsSignal TransductionSudden DeathTechnologyTestingTherapeuticTreatment EfficacyWorkbasecell typedesigner receptors exclusively activated by designer drugsdravet syndromehuman diseasehuman modelinnovationmanmortalitymouse modelnervous system disorderneuronal circuitryneurotransmissionnoveloptogeneticspre-clinicalpreventprotective effectraphe nucleirespiratoryresponsereuptakeserotonin 7 receptorserotonin receptorsudden unexpected death in epilepsytransmission process
项目摘要
PROJECT SUMMARY/ABSTRACT
The risk of sudden unexpected death in epilepsy (SUDEP) in patients with epilepsy is more than 20-fold higher
than that of death in the general population. Clinical and animal studies show that seizure-induced respiratory
arrest is the primary event leading to death. Increased serotonin (5-HT) levels in the brain reduce seizure-
induced respiratory arrest in provoked seizure models. However, it is unclear whether enhancing 5-HT neuro-
transmission exerts protective effects on seizure-induced sudden death in spontaneous seizure (epilepsy)
models and which 5-HT circuitry is involved in this sudden death in both provoked and spontaneous seizure
models. These gaps in knowledge have significantly hindered the therapeutics to prevent SUDEP in patients.
The long-term goal is to foster effective prevention strategies against SUDEP using approaches targeted to
specific SUDEP mechanisms. The overall objectives of this proposal are to (1) determine the efficacy of 5-HT-
enhancing agents in suppressing seizure-induced sudden death and (2) elucidate the involved 5-HT circuitry
mechanisms in animal models, especially in a widely-used mouse model of human Dravet syndrome (a type of
epilepsy) that displays spontaneous seizures with a high rate of seizure-induced sudden death. The central
hypothesis is that enhanced 5-HT signaling prevents seizure-induced sudden death, and that the 5-HT raphe-
amygdala circuitry is involved in this sudden death in DBA/1 and Dravet mice. The rationale for this proposal is
that a determination of preclinical therapeutic efficacy of 5-HT-enhancing agents and 5-HT neuronal circuitry
mechanisms in seizure-induced sudden death is likely to offer a strong scientific framework by which new
strategies against human SUDEP can be developed. The central hypothesis will be tested in the following two
specific aims: 1) Determine the protective effects of enhancing 5-HT neurotransmission on seizure-induced
sudden death in DBA/1 and Dravet mice; and 2) Elucidate how 5-HT circuitry from raphe nuclei to the amygda-
la modifies seizure-induced sudden death in DBA/1 and Dravet mice. We will employ a combination of simul-
taneous video EEG/ECG/plethysmography monitoring, electrophysiology, pharmacology and cell-type specific
technologies (optogenetics and DREADDs) to perform the work in these aims. The proposed research is inno-
vative because it defines a novel 5-HT circuitry mechanism of seizure-induced sudden death using optogenet-
ics and DREADDs in animal models, especially in a human disease model, which could conceptually advance
the knowledge on the pathophysiological mechanisms of SUDEP. The proposed work is significant because
the expected outcomes will potentially foster targeted pharmacologic and neurostimulatory interventions of
SUDEP to save lives of at-risk patients.
项目摘要/摘要
癫痫患者发生癫痫猝死(SUDEP)的风险高出20倍以上
而不是普通人群中的死亡。临床和动物研究表明,癫痫发作诱导的呼吸道
逮捕是导致死亡的首要事件。大脑中5-羟色胺(5-HT)水平的增加减少了癫痫发作-
诱发惊厥模型的诱导呼吸骤停。然而,目前尚不清楚是否增强5-羟色胺神经-
传递对自发性癫痫(癫痫)致痫性猝死的保护作用
以及在诱发性和自发性癫痫发作中,哪个5-羟色胺回路参与了这种猝死
模特们。这些知识上的差距严重阻碍了预防患者SUDEP的治疗方法。
长期目标是制定有效的预防战略,使用有针对性的方法来预防SUDEP
特定的SUDEP机制。这项建议的总体目标是:(1)确定5-羟色胺的疗效。
抑制癫痫猝死的增强剂和(2)阐明涉及的5-羟色胺回路
动物模型中的机制,特别是在广泛使用的人类Drave综合症(一种
癫痫),表现为自发性癫痫发作,癫痫导致猝死的比率很高。中环
假说认为,增强的5-羟色胺信号可防止癫痫导致的猝死,而5-羟色胺中缝-
DBA/1和Dravet小鼠的这种猝死与杏仁核回路有关。这项提议的理由是
5-羟色胺增强剂和5-羟色胺神经元环路临床前疗效的测定
癫痫诱发猝死的机制可能提供一个强有力的科学框架,通过
可以开发出针对人类SUDEP的策略。核心假设将在以下两个方面得到检验
具体目的:1)确定增强5-羟色胺神经递质对癫痫的保护作用
DBA/1和Dravet小鼠猝死;2)阐明5-羟色胺从中缝核团到杏仁核的回路是如何-
LA可改善DBA/1和Dravet小鼠癫痫诱发的猝死。我们将采用SIMUL-2的组合
同时视频脑电/心电/体积描记监测、电生理学、药理学和细胞类型特异性
技术(光遗传学和DREADD)来执行这些目标的工作。这项拟议的研究是徒劳的-
这是因为它定义了一种新的5-羟色胺回路机制,利用光遗传学-
动物模型中的ICS和DREADD,特别是在人类疾病模型中,这在概念上可能会
对SUDEP的病理生理机制的认识。拟议的工作意义重大,因为
预期的结果可能会促进有针对性的药物和神经刺激干预
SUDEP以挽救高危患者的生命。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Huajun Feng其他文献
Huajun Feng的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Huajun Feng', 18)}}的其他基金
Prevention of Seizure-Induced Sudden Death by Stimulating Serotonergic Signaling
通过刺激血清素信号传导预防癫痫引起的猝死
- 批准号:
10532216 - 财政年份:2020
- 资助金额:
$ 38.19万 - 项目类别:
Prevention of Seizure-Induced Sudden Death by Stimulating Serotonergic Signaling
通过刺激血清素信号传导预防癫痫引起的猝死
- 批准号:
10116505 - 财政年份:2020
- 资助金额:
$ 38.19万 - 项目类别:
Monoamine-Mediated Arousal to Prevent Seizure-Induced Sudden Death
单胺介导的唤醒可预防癫痫引起的猝死
- 批准号:
9297506 - 财政年份:2017
- 资助金额:
$ 38.19万 - 项目类别:
Role of Central 5-HT Transmission in Respiratory Arrest Induced by Seizures
中枢 5-HT 传输在癫痫发作引起的呼吸骤停中的作用
- 批准号:
8283020 - 财政年份:2012
- 资助金额:
$ 38.19万 - 项目类别:
Role of Central 5-HT Transmission in Respiratory Arrest Induced by Seizures
中枢 5-HT 传输在癫痫发作引起的呼吸骤停中的作用
- 批准号:
8437157 - 财政年份:2012
- 资助金额:
$ 38.19万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 38.19万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 38.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 38.19万 - 项目类别: